SG11201609652RA - Treatment of polybacterials infections - Google Patents
Treatment of polybacterials infectionsInfo
- Publication number
- SG11201609652RA SG11201609652RA SG11201609652RA SG11201609652RA SG11201609652RA SG 11201609652R A SG11201609652R A SG 11201609652RA SG 11201609652R A SG11201609652R A SG 11201609652RA SG 11201609652R A SG11201609652R A SG 11201609652RA SG 11201609652R A SG11201609652R A SG 11201609652RA
- Authority
- SG
- Singapore
- Prior art keywords
- polybacterials
- infections
- treatment
- polybacterials infections
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014506P | 2014-06-19 | 2014-06-19 | |
| US201562140849P | 2015-03-31 | 2015-03-31 | |
| PCT/US2015/036576 WO2015196011A1 (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201609652RA true SG11201609652RA (en) | 2016-12-29 |
Family
ID=54936121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609652RA SG11201609652RA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
| SG10201811361XA SG10201811361XA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811361XA SG10201811361XA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11168132B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3157565B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6845016B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102549870B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106456767B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015276938B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2952278A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2983252T3 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201609652RA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI719938B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015196011A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2718320T (lt) | 2011-06-10 | 2018-04-10 | Medimmune Limited | Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas |
| MX374826B (es) | 2011-11-07 | 2025-03-06 | Medimmune Llc | Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas. |
| KR102272744B1 (ko) | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| EP3640338A1 (en) * | 2012-11-06 | 2020-04-22 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| WO2017095744A1 (en) | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Method for preventing or treating nosocomial pneumonia |
| KR20190025826A (ko) * | 2016-05-05 | 2019-03-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물 |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| BR112021001214A2 (pt) | 2018-07-24 | 2021-04-27 | Medimmune, Llc | anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus |
| CN113015745B (zh) | 2018-10-09 | 2025-02-11 | 免疫医疗有限责任公司 | 针对金黄色葡萄球菌白细胞毒素的抗体 |
| US11168133B2 (en) | 2018-10-09 | 2021-11-09 | Medimmune, Llc | Combinations of anti-Staphylococcus aureus antibodies |
| GB201816554D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| WO2020172233A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Treatment of prostate cancer by androgen ablation and il-8 blockade |
| WO2020185986A1 (en) * | 2019-03-13 | 2020-09-17 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
| MX2021015156A (es) * | 2019-06-11 | 2022-01-18 | Regeneron Pharma | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. |
| US20220259290A1 (en) * | 2019-07-24 | 2022-08-18 | Japan Science And Technology Agency | Innovative production technique for antibody-enzyme |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| WO2025117765A1 (en) * | 2023-12-01 | 2025-06-05 | University Of Washington | Protective monoclonal antibodies to pseudomonas aeruginosa |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2043690A1 (en) | 2006-06-12 | 2009-04-08 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| CA2784033A1 (en) | 2009-12-22 | 2011-07-21 | Kalobios Pharmaceuticals, Inc. | A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection |
| CN107474133B (zh) | 2011-02-08 | 2021-10-15 | 米迪缪尼有限公司 | 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法 |
| MX374826B (es) * | 2011-11-07 | 2025-03-06 | Medimmune Llc | Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas. |
| SG11201502937PA (en) * | 2012-11-06 | 2015-06-29 | Medimmune Llc | COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES |
| KR102272744B1 (ko) | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| EP3640338A1 (en) | 2012-11-06 | 2020-04-22 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
-
2015
- 2015-06-18 TW TW104119861A patent/TWI719938B/zh active
- 2015-06-19 US US15/319,958 patent/US11168132B2/en active Active
- 2015-06-19 CA CA2952278A patent/CA2952278A1/en active Pending
- 2015-06-19 AU AU2015276938A patent/AU2015276938B2/en active Active
- 2015-06-19 JP JP2016573926A patent/JP6845016B2/ja active Active
- 2015-06-19 SG SG11201609652RA patent/SG11201609652RA/en unknown
- 2015-06-19 CN CN201580032548.7A patent/CN106456767B/zh active Active
- 2015-06-19 WO PCT/US2015/036576 patent/WO2015196011A1/en not_active Ceased
- 2015-06-19 ES ES15809174T patent/ES2983252T3/es active Active
- 2015-06-19 SG SG10201811361XA patent/SG10201811361XA/en unknown
- 2015-06-19 EP EP15809174.4A patent/EP3157565B1/en active Active
- 2015-06-19 KR KR1020167034742A patent/KR102549870B1/ko active Active
-
2020
- 2020-12-18 JP JP2020209896A patent/JP2021063090A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201613575A (en) | 2016-04-16 |
| EP3157565A1 (en) | 2017-04-26 |
| TWI719938B (zh) | 2021-03-01 |
| JP6845016B2 (ja) | 2021-03-17 |
| SG10201811361XA (en) | 2019-01-30 |
| JP2021063090A (ja) | 2021-04-22 |
| AU2015276938B2 (en) | 2020-11-19 |
| EP3157565B1 (en) | 2024-04-24 |
| KR102549870B1 (ko) | 2023-06-29 |
| CA2952278A1 (en) | 2015-12-23 |
| WO2015196011A1 (en) | 2015-12-23 |
| CN106456767A (zh) | 2017-02-22 |
| CN106456767B (zh) | 2021-07-09 |
| JP2017519768A (ja) | 2017-07-20 |
| AU2015276938A1 (en) | 2017-01-05 |
| US11168132B2 (en) | 2021-11-09 |
| US20170129943A1 (en) | 2017-05-11 |
| KR20170015329A (ko) | 2017-02-08 |
| ES2983252T3 (es) | 2024-10-22 |
| EP3157565A4 (en) | 2018-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252839A0 (en) | Treatment of boils | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| GB201701673D0 (en) | Methods of well treatment | |
| SG11201702688UA (en) | Methods of treating rsv infections | |
| GB201502137D0 (en) | Treatment | |
| GB201410116D0 (en) | Method of treatment | |
| IL246880A0 (en) | Tumor treatment | |
| IL254825A0 (en) | Methods of treatment with Tesalisib | |
| SG11201610243YA (en) | Treatment of severe hypertriglyceridemia | |
| IL253028B (en) | treatment method | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201519450D0 (en) | Novel treatment | |
| IL255498A (en) | Treatment of pruritus | |
| GB201408297D0 (en) | Treatment of cancer | |
| GB201402909D0 (en) | Treating infection | |
| EP3091985A4 (en) | Treatment of migraines | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201411027D0 (en) | Treatment | |
| GB201512139D0 (en) | Methods of treatment | |
| EP3122363A4 (en) | Treatment of autism | |
| GB201412411D0 (en) | Treatment | |
| GB201407806D0 (en) | Treatment of fibrosis | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201522257D0 (en) | Treatment of autism | |
| GB201421982D0 (en) | Method of treatment |